NeuroOne Medical TechnologiesNMTC
NMTC
About: NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Employees: 17
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2.62% less ownership
Funds ownership: 7.87% [Q3] → 5.25% (-2.62%) [Q4]
5% less funds holding
Funds holding: 21 [Q3] → 20 (-1) [Q4]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
44% less capital invested
Capital invested by funds: $2.4M [Q3] → $1.34M (-$1.06M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NMTC.
Financial journalist opinion
Based on 4 articles about NMTC published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Submission for New Intended Use That Leverages Company's Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company's patented OneRF® Technology Platform.
Neutral
GlobeNewsWire
1 week ago
NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025.
Neutral
Seeking Alpha
4 weeks ago
NeuroOne Medical Technologies Corporation (NMTC) Q1 2025 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Dave Rosa - CEO Ron McClurg - CFO Chris Volker - COO Operator Good day, ladies and gentlemen. Welcome to the First Quarter of Fiscal Year 2025 Financial Results Conference Call for NeuroOne Medical Technologies Corporation.
Neutral
GlobeNewsWire
4 weeks ago
NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update
Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Regains Compliance with Nasdaq Listing Requirements
EDEN PRAIRIE, Minn., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has regained compliance with the Nasdaq Capital Market's continued listing standard for the minimum share price requirements under Nasdaq Listing Rule 5550(a)(2).
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue
Neutral
Seeking Alpha
2 months ago
Stock Picks From Seeking Alpha's December 2024 New Analysts
In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne Medical, X-Fab Silicon Foundries, and ArcerlorMittal. Analysts' recommendations range from Strong Buy to Strong Sell, covering diverse sectors such as healthcare, technology, energy, and consumer goods.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will hold a virtual roadshow webinar to discuss its business operations and recent updates.
Neutral
Seeking Alpha
2 months ago
NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q4 2024 Earnings Conference Call December 17, 2024 9:00 AM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Fourth Quarter and Fiscal Year-End 2024 Earnings Call.
Charts implemented using Lightweight Charts™